NICE UK approves use of anti-CGRP monoimmune Ajovy to prevent migraines, with patients only need to inject themselves once a month or quarter

The National Institutes of Health and Health (NICE) recommends teva's anti-cecalingene-related peptide (CGRP) monoantigen Ajovy to prevent chronic migraines, which have previously been used with at least three prophylactic therapies and have no responsethe decision means that Ajovy became the first anti-CGRP prophylaxis recommended by NICE, with patients only given once a month or quarter and have the option of self-injection after trainingat least half of migraine sufferers are diagnosed and undertreatedLess than half of migraine sufferers will seek medical attention, and less than 30 percent of migraine sufferers can control their conditionIt usually manifests as moderate to severe headaches, accompanied by nausea or vomiting, sensitivity to noise, light or odorlast year, Teva also received European Commission approval under two major Phase III clinical trials in which patients treated for migraines significantly reduced the number of migraine days per month by at least 50 percent, with disease relief as early as one week after treatmentone in seven adults in the UK (more than 7.2 million people) suffer from migraines, while women are three times more likely to suffer from migraines than men